Down Syndrome Prenatal Screening and Diagnosis: Tests, Timing, and Decision-Making

Multiple options exist to assess fetal risk for trisomy 21 (Down syndrome). Choice depends on gestational age, risk tolerance, and values.

Screening Tests (Risk Estimation)

First Trimester (11–13+6 weeks)

  • Combined test: Nuchal translucency (NT) ultrasound + maternal serum PAPP-A, free β-hCG. Detection ~85–90%, FPR 5%.
  • Cell-free DNA (NIPT): Fetal fraction from maternal blood; >99% detection, <0.1% FPR for T21. Also screens T18, T13, sex chromosomes.

Second Trimester (15–22 weeks)

  • Quad screen: AFP, hCG, estriol, inhibin-A. Detection ~81%, FPR 5%.
  • Integrated/sequential: Combines 1st + 2nd trimester markers.

Diagnostic Tests (Definitive)

  • CVS (10–13 weeks): Chorionic villus sampling; karyotype/CMA. Miscarriage risk ~0.2–0.5%.
  • Amniocentesis (15–20+ weeks): Amniotic fluid karyotype/CMA. Risk ~0.1–0.3%.

Decision Framework

  • Screening → if high risk → diagnostic confirm.
  • NIPT increasingly used as primary screen (cost/access permitting).
  • Diagnostic offered directly if: age ≥35, prior affected pregnancy, ultrasound anomalies, parental translocation.

Counseling Essentials

  • Non-directive; explore values, preparation, termination vs. continuation resources.
  • Support organizations (NDSC, DSE, local groups).

Informed choice requires understanding test limitations (screening ≠ diagnosis) and personal priorities.

Pregnancy & Health - Related Articles